Literature DB >> 7515031

SCLC-cluster-2 antibodies detect the pancarcinoma/epithelial glycoprotein EGP-2.

L De Leij1, W Helrich, R Stein, M J Mattes.   

Abstract

Analysis of the antibodies submitted to the 3 International Workshops on Small Cell Lung Cancer Antigens has resulted in the identification of 15 clusters of antibody reactivity. One of these clusters, named SCLC cluster 2, is characterized by reactivity against an epithelium-associated 38 kDa membrane glycoprotein. SCLC cluster 2, and a number of other antibodies with reportedly similar reactivities, were shown to recognize a protein encoded by the GA733-2 gene, whereas the newly defined SCLC cluster 13 antibodies react with the GA733-1 gene product. We propose to call the antigen detected by SCLC-cluster-2 antibodies "epithelial glycoprotein 2" (EGP-2), and the epithelium-associated glycoprotein recognized by antibodies clustered in SCLC cluster 13 (see elsewhere in this volume) "epithelial glycoprotein 1" (EGP-1). A short overview of the characteristics of both proteins and the applications of anti-EGP-2 antibodies is presented.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7515031     DOI: 10.1002/ijc.2910570713

Source DB:  PubMed          Journal:  Int J Cancer Suppl        ISSN: 0898-6924


  12 in total

1.  Epidermal growth factor-like repeats mediate lateral and reciprocal interactions of Ep-CAM molecules in homophilic adhesions.

Authors:  M Balzar; I H Briaire-de Bruijn; H A Rees-Bakker; F A Prins; W Helfrich; L de Leij; G Riethmüller; S Alberti; S O Warnaar; G J Fleuren; S V Litvinov
Journal:  Mol Cell Biol       Date:  2001-04       Impact factor: 4.272

2.  Staphylococcal acid phosphatase binds to endothelial cells via charge interaction; a pathogenic role in Wegener's granulomatosis?

Authors:  R H Brons; H I Bakker; R T Van Wijk; N W Van Dijk; A C Muller Kobold; P C Limburg; W L Manson; C G Kallenberg; J W Tervaert
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

3.  MMTV/LTR Promoter-Driven Transgenic Expression of EpCAM Leads to the Development of Large Pancreatic Islets.

Authors:  Jeffrey R Vercollone; Maarten Balzar; Sergey V Litvinov; Wendy Yang; Vincenzo Cirulli
Journal:  J Histochem Cytochem       Date:  2015-08       Impact factor: 2.479

4.  Absence of cell-surface EpCAM in congenital tufting enteropathy.

Authors:  Ulrike Schnell; Jeroen Kuipers; James L Mueller; Anneke Veenstra-Algra; Mamata Sivagnanam; Ben N G Giepmans
Journal:  Hum Mol Genet       Date:  2013-03-05       Impact factor: 6.150

Review 5.  Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule.

Authors:  Monika Trzpis; Pamela M J McLaughlin; Lou M F H de Leij; Martin C Harmsen
Journal:  Am J Pathol       Date:  2007-06-28       Impact factor: 4.307

6.  A quantitative reverse transcriptase polymerase chain reaction-based assay to detect carcinoma cells in peripheral blood.

Authors:  W Helfrich; R ten Poele; G J Meersma; N H Mulder; E G de Vries; L de Leij; E F Smit
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  CD3 directed bispecific antibodies induce increased lymphocyte-endothelial cell interactions in vitro.

Authors:  G Molema; J W Tervaert; B J Kroesen; W Helfrich; D K Meijer; L F de Leij
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

8.  Nanodiamonds as multi-purpose labels for microscopy.

Authors:  S R Hemelaar; P de Boer; M Chipaux; W Zuidema; T Hamoh; F Perona Martinez; A Nagl; J P Hoogenboom; B N G Giepmans; R Schirhagl
Journal:  Sci Rep       Date:  2017-04-07       Impact factor: 4.379

9.  EpCAM proteolysis: new fragments with distinct functions?

Authors:  Ulrike Schnell; Jeroen Kuipers; Ben N G Giepmans
Journal:  Biosci Rep       Date:  2013-03-19       Impact factor: 3.840

10.  Immunomodulatory effects of intravenous BIS-1 F(ab')2 administration in renal cell cancer patients.

Authors:  R A Janssen; B J Kroesen; J Buter; G Mesander; D T Sleijfer; T H The; N H Mulder; L de Leij
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.